Clin2
NCT07561125Possibly a fitRecruiting

IVIG for lung disease in very preterm infants

Bronchopulmonary Dysplasia

Treatments studied

Part of Genetic & congenital, Lungs & breathing clinical trials.

This trial tests whether giving intravenous immunoglobulin (IVIG) early after birth can help prevent or treat a serious lung condition called bronchopulmonary dysplasia (BPD) in babies born at 28 weeks or earlier. It may help reduce the need for breathing support and oxygen.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
29 people
Ages
1 day to 2 months
Study type
Interventional

Who can take part

  • Your baby was born at 28 weeks and 6 days of pregnancy or earlier
  • Your baby is admitted to the hospital within 24 hours after birth
  • Your baby has breathing problems and chest X-ray changes that suggest bronchopulmonary dysplasia (BPD)
  • Your baby does not have major birth defects, chromosome problems, severe brain bleeding, or severe lung infection
  • Your baby does not have other serious conditions that could affect breathing or development

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06925360Recruiting· Phase 2
IVIG for lung disease in premature babies

This trial tests if intravenous immunoglobulin (IVIG) can help prevent or treat bronchopulmonary dysplasia (BPD), a lung condition in premature babies. It is for very preterm infants born between 25 and 29 weeks who show early signs of BPD and are enrolled in the first day of life.

Shanghai, Shanghai Municipality
NCT06279741Recruiting· Phase 1/Phase 2
Cell therapy to prevent lung disease in very premature babies

This study tests whether a special cell therapy (MSC-EVs) given to extremely premature babies can help prevent a serious lung disease called bronchopulmonary dysplasia (BPD). The treatment is given while the baby is still on a breathing machine.

Brussels
NCT03631420Recruiting· Phase 1
Stem cell treatment to prevent lung disease in very premature babies

This Phase 1 trial tests whether giving stem cells into a breathing tube is safe and may help prevent bronchopulmonary dysplasia (BPD), a serious lung condition in very premature infants. It focuses on babies soon after birth who already need breathing support and are at risk.

Tainan
NCT06897839Recruiting· Phase 2/Phase 3
Testing zelpultide alfa for preterm babies at risk of lung disease

This trial tests a medicine called zelpultide alfa in very premature babies who are at high risk of developing bronchopulmonary dysplasia (BPD), a chronic lung disease. The goal is to see if it can help prevent or lessen lung problems compared to standard care alone.

Buenos Aires
NCT06443528Not yet recruiting
Lung ultrasound to predict BPD in early preterm babies

This study is testing whether a simple ultrasound of the lungs done right after birth can help predict a lung problem called bronchopulmonary dysplasia (BPD) in very early preterm babies. If successful, this could help doctors identify babies at high risk sooner and provide better care.

NCT06475976Recruiting
Identifying lung types in severe BPD in preemies

This study looks at babies born very early who have severe lung disease (grade 3 BPD) and still need a breathing machine. Researchers will use tests to understand their lung problems better, which may help guide their care.

Philadelphia, Pennsylvania

Hear when a new Bronchopulmonary Dysplasia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.